MRD Monitoring in Acute Myeloid Leukemia

Introduction to measurable residual disease (MRD)Подробнее

MRD monitoring for TP53 post-alloSCT predicts outcomes to eprenetapopt + azacitidineПодробнее

Multiparameter Approach to CLL Diagnosis, Prognostic Biomarker Assessment, and MRD MonitoringПодробнее

Cytometry versus morphology in the monitoring of AMLПодробнее

MRD as a monitoring technique of alloSCT and CAR-T in AML/ALLПодробнее

AML ETO t(8;21) GENE REARRANGEMENT QUANTITATIVE MRD MONITORПодробнее

Can peripheral blood MRD monitoring supplement bone marrow monitoring?Подробнее

“How I treat” a patient with AML in remission after intensive chemotherapy not proceeding to HSCTПодробнее

Level Up your MRD Testing: Leveraging Standardized & Sensitive AML AssessmentsПодробнее

How can we apply MRD guidelines to low-intensity therapy in AML?Подробнее

The role of molecular MRD monitoring in AML/NGS approachesПодробнее

The importance of MRD monitoring in patients with AMLПодробнее

Personalizing AML treatment by targeting MRD mutationsПодробнее

ACUTE MYELOID LEUKEMIAS-UPDATED 2022Подробнее

Minimal Residual Disease (MRD) in Acute Myeloid Leukemia- Are we Ready for Individualized Risk As...Подробнее

Development of Molecular AML MRD AssaysПодробнее

Post-HCT relapse monitoring and managementПодробнее

MRD testing in acute leukaemia - Gregor Hoermann, MD, PhDПодробнее

Updates on the use of molecular monitoring to detect MRD in AMLПодробнее

How can serial MRD monitoring be utilized to improve relapse outcomes?Подробнее